Is Dr Reddy’s Q3 profit down by 14% to Rs 1,210 crore?
Synopsis
Dr Reddy's Laboratories has reported a significant drop in its net profit for Q3 FY26, raising questions about future performance. While the revenue has shown growth, challenges in specific markets and declining margins suggest a complex landscape for the pharmaceutical giant.
Key Takeaways
Net profit fell by 14% to Rs 1,209.8 crore.
Revenue increased by 4.4% to Rs 8,726.8 crore.
EBITDA decreased by 10.8% to Rs 2,049.3 crore.
Growth observed in Europe (20%), India (19%), and emerging markets (32%).
Research spending down by 8% to Rs 610 crore.
Mumbai, Jan 21 (NationPress) Dr Reddy's Laboratories announced a 14% drop in its consolidated net profit for the December quarter (Q3) of FY26. The pharmaceutical company reported a consolidated net profit of Rs 1,209.8 crore in Q3 FY26, a decrease from Rs 1,413.3 crore in the same quarter of the previous fiscal year, as per their stock exchange notification.
In terms of revenue, operations for the quarter grew by 4.4%, totaling Rs 8,726.8 crore, up from Rs 8,358.6 crore in the corresponding period last year, driven by growth in most significant markets.
Operating performance saw EBITDA fall by 10.8% year-on-year, landing at Rs 2,049.3 crore.
Moreover, the company experienced pressure on its gross margins, which decreased to 53.6% in Q3 FY26 compared to 58.7% in Q3 FY25 and 54.7% in the preceding quarter, as indicated in the company's report.
Dr Reddy's highlighted that growth was widespread across regions, with the exception of its North America Generics segment, which faced a decline primarily due to reduced sales of Lenalidomide.
Favorable foreign exchange rates contributed positively to the overall growth.
Global generics revenue reached Rs 1,791 crore in Q3 FY26, showcasing a 7% year-on-year increase and a 1% sequential rise.
Despite North America Generics, the company’s main revenue source, experiencing a 12% decline, other regions performed strongly, with Europe increasing by 20%, India growing by 19%, and emerging markets soaring by 32%.
The Pharmaceutical Services and Active Ingredients (PSAI) division reported a 2% year-on-year revenue decrease, totaling Rs 800 crore in the quarter.
Research and development expenditure fell to Rs 610 crore, down by 8% year-on-year, mainly due to reduced investments in biosimilars following the completion of significant spending related to Abatacept.
The company stated that its R&D efforts will continue to focus on complex generics, biosimilars, peptides, and innovative biologics.
Point of View
Dr Reddy’s latest financial report underscores the complexities facing pharmaceutical companies today. While many regions show promising growth, the significant decline in North America highlights the challenges within that market. It's essential for stakeholders to consider these dynamics as we navigate the ever-evolving landscape of healthcare and pharmaceuticals.
NationPress
6 May 2026
Frequently Asked Questions
What caused the decline in Dr Reddy's profit?
The decline in profit is primarily attributed to lower sales in the North America Generics business and pressure on gross margins.
How did the revenue perform in Q3 FY26?
Revenue from operations grew by 4.4% in Q3 FY26, reaching Rs 8,726.8 crore.
What is the focus of Dr Reddy's R&D efforts?
Dr Reddy's R&D efforts are focused on complex generics, biosimilars, peptides, and novel biologics.
Which regions showed growth for Dr Reddy's?
Europe, India, and emerging markets showed strong growth, with increases of 20%, 19%, and 32%, respectively.
What was the EBITDA for Dr Reddy's in Q3 FY26?
The EBITDA for Q3 FY26 was Rs 2,049.3 crore, reflecting a 10.8% decline year-on-year.
